AVALIAÇÃO DA SEGURANÇA NO USO DE IMUNOBIOLÓGICOS PARA TRATAMENTO DA PSORÍASE EM GESTANTES E LACTANTES: UMA REVISÃO SISTEMÁTICA
DOI:
https://doi.org/10.36557/2674-8169.2025v7n5p1363-1379Keywords:
psoriasis, pregnancy, lactation, breastfeeding, biological therapyAbstract
Introduction: Psoriasis is a chronic immune-inflammatory disease that affects 3% of the global population. During pregnancy and lactation, its course is unpredictable, with reports of worsening. Thus, biological agents have become a therapeutic option. Objective: To assess the safety of using biological agents for the treatment of psoriasis in pregnant and lactating women. Methodology: Systematic review based on data from PubMed, Virtual Health Library, and EBSCO, using 11 articles published between 2020 and 2025. Results: 72% of the analyzed articles demonstrate safety and efficacy in the use of biological agents in patients with severe or refractory forms of the disease. The rate of spontaneous abortions and congenital anomalies was similar to that of the general population. Certolizumab pegol stood out as the safest biological agent due to its minimal placental transfer. Conclusion: The use of biological agents may be safe, provided that a risk-benefit analysis is conducted and follow-up is carried out by specialists. Moreover, there is lower placental transfer of medications when used during the first trimester of pregnancy. Among those evaluated, certolizumab pegol is the first-line therapy. This highlights the need for individualized perigestational care, aiming at the well-being of the mother-fetus dyad.
Downloads
References
Azulay-Abulafia L, Antônio P, Felix O, Colaboradores A, Gripp, Cursi I. CAPÍTULO IMUNOBIOLÓGICOS NA PSORÍASE [Internet]. Available from: https://www.saudedireta.com.br/docsupload/1340102233Capitulo11.pdf
Reid C, Griffiths C. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Dermato Venereologica. 2020;100(3):70–80.
Petit RG, Cano A, Ortiz A, Espina M, Prat J, Muñoz M, et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. International Journal of Molecular Sciences [Internet]. 2021 Jan 1;22(9):4983. Available from: https://www.mdpi.com/1422-0067/22/9/4983/htm
McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: An Update - Part I: Pregnancy. Journal of the American Academy of Dermatology. 2024 Jan 1;
Strain J, Leis M, Lee KO, Fleming P. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy. Skin therapy letter [Internet]. 2021 Mar;26(2):1–5. Available from: https://pubmed.ncbi.nlm.nih.gov/33769772/
Mahadevan U, Naureckas S, Tikhonov I, Wang Y, Lin CB, Geldhof A, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer’s global safety database. Alimentary pharmacology & therapeutics [Internet]. 2022 Aug;56(3):477–90. Available from: https://pubmed.ncbi.nlm.nih.gov/35560249/
Kimball AB, Guenther L, Kalia S, de Jong EMGJ, Lafferty KP, Chen DY, et al. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology [Internet]. 2021 Mar 1 [cited 2022 Jan 23];157(3):301–6. Available from: https://jamanetwork.com/journals/jamadermatology/article-abstract/2775503
Babuna Kobaner G, Polat Ekinci A. Use of biologic therapies for psoriasis during pregnancy and long‐term outcomes of exposed children: A 14‐year real‐life experience at a tertiary center in Turkey and review of the literature. Dermatologic Therapy. 2020 Nov;33(6).
Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021 Jul;22(4):425-442. doi:10.1007/s40257-021-00603-w. Epub 2021 Apr 16. PMID: 33861409; PMCID: PMC8051287.
V. Sánchez‐García, R. Hernández‐Quiles, E. de‐Miguel‐Balsa, Á. Giménez‐Richarte, Ramos‐Rincón JM, I. Belinchón‐Romero. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2023 Jun 1;37(10):1971–90.
Antonella Di Cesare, Federica Ricceri, Rosi E, Maria Thais Fastame, Prignano F. Therapy of PsO in Special Subsets of Patients. Biomedicines. 2022 Nov 10;10(11):2879–9.
Jeong YD, Jo H, Cho H, Jang W, Park J, Lee S, et al. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. International Archives of Allergy and Immunology. 2024 Dec 3;1–15.
Boggs E, Griffin L, Ahmad K, Hackett C, Ramsay B, Lynch M. A retrospective review of pregnancies on biologics for the treatment of dermatological conditions. Clinical and Experimental Dermatology. 2020 May 2;45(7):880–3.
Siffel C, Correa A, Cragan J, Alverson C. Prenatal diagnosis, pregnancy terminations and prevalence of Down syndrome in Atlanta. Birth Defects Research Part A: Clinical and Molecular Teratology. 2004;70(9):565–71.
Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. British Journal of Dermatology. 2016 Jul 24;175(3):464–72.
Yaghi M, McMullan P, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: An update-Part II: Lactation. Journal of the American Academy of Dermatology [Internet]. 2024 Oct;91(4):651–68. Available from: https://pubmed.ncbi.nlm.nih.gov/38280680/
Andersen AM . N. Maternal age and fetal loss: population based register linkage study. BMJ. 2000 Jun 24;320(7251):1708–12.
Diretrizes para autores | Revista Temas em Educação [Internet]. Ufpb.br. 2024 [cited 2025 Apr 22]. Available from: https://periodicos.ufpb.br/index.php/rteo/authors.
Imunogenicidade dos fármacos imunobiológicos [Internet]. Sociedade Paulista de Reumatologia. 2023. Available from: https://www.reumatologiasp.com.br/artigos/imunogenicidade-dos-farmacos-imunobiologicos/
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar 1;33(1):159–74.
Silva DLF da, Secamilli EN, Beleli MV, Massuda JY, Franca AFEC, Magalhães RF. Immunobiologicals in dermatology. Anais Brasileiros de Dermatologia. 2022 May;97(3):275–83.
Slattery MM, Morrison JJ. Preterm delivery. The Lancet. 2002 Nov;360(9344):1489–97.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zuleide Barros Luna Gomes, Cássia Fernanda dos Santos Rosa, Thamara Cristiane Batista Alves Morita, Victoria Santos Moura
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
